🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Tamara S. Rodems

Therapeutics Clinical Research

ORCID: 0000-0001-6582-9379

Also affiliated with Fate Therapeutics (United States)

Immunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma”.

Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma

Molecular Oncology(2021)10.1002/1878-0261.12931

N/A

0.959DataRank · unranked

22 citations

Jennifer L. Schehr, Hamid Emamekhoo, Benjamin K. Gibbs, Tamara S. Rodems, Matthew C. Mannino +16 more

Reversible Epigenetic Alterations Regulate Class I HLA Loss in Prostate Cancer

Research Square(2021)10.21203/rs.3.rs-894353/v1

N/A

0.292DataRank · unranked

6 citations

Erika Henninger, Charlotte N. Stahlfeld, Cole S. Gilsdorf, Kristin N. Carlson, Madison Kircher +8 more

AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3142

N/A

0DataRank · unranked

49 citations

Mari Iida, Kwangok P. Nickel, Colin A. Longhurst, Samantha R. Fischbach, Tamara S. Rodems +15 more

Reversible epigenetic alterations regulate class I HLA loss in prostate cancer

Communications Biology(2022)10.1038/s42003-022-03843-6

N/A

0DataRank · unranked

52 citations

Erika Héninger, Charlotte N. Stahlfeld, Cole S. Gilsdorf, Kristin N. Carlson, Madison Kircher +8 more